Natera Inc Stock Today
NTRA Stock | USD 148.22 5.71 4.01% |
PerformanceVery Weak
| Odds Of DistressLow
|
Natera is trading at 148.22 as of the 17th of March 2025, a 4.01 percent increase since the beginning of the trading day. The stock's open price was 142.51. Natera has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on December 6, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Natera Inc's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of July 2015 | Category Healthcare | Classification Health Care |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Natera, Inc. was founded in 2003 and is based in Austin, Texas. Natera operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 135.19 M outstanding shares of which 2.49 M shares are now shorted by private and institutional investors with about 1.63 trading days to cover. More on Natera Inc
Moving together with Natera Stock
Moving against Natera Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Natera Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
CEO Director | Steven Chapman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, ARCA Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Healthcare, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNatera can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Natera's financial leverage. It provides some insight into what part of Natera's total assets is financed by creditors.
|
Natera Inc (NTRA) is traded on NASDAQ Exchange in USA. It is located in 13011 McCallen Pass, Austin, TX, United States, 78753 and employs 4,424 people. Natera is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 20.04 B. Natera Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 135.19 M outstanding shares of which 2.49 M shares are now shorted by private and institutional investors with about 1.63 trading days to cover.
Natera Inc currently holds about 638.65 M in cash with 135.66 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59.
Check Natera Probability Of Bankruptcy
Ownership AllocationNatera Inc maintains a total of 135.19 Million outstanding shares. The majority of Natera outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Natera Inc to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Natera Inc. Please pay attention to any change in the institutional holdings of Natera as this could imply that something significant has changed or is about to change at the company. On December 6, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Natera Inc's common stock.
Check Natera Ownership Details
Natera Stock Institutional Holders
Instituion | Recorded On | Shares | |
Geode Capital Management, Llc | 2024-12-31 | 2.2 M | |
Kynam Capital Management, Lp | 2024-12-31 | 2 M | |
Ameriprise Financial Inc | 2024-12-31 | 2 M | |
Amvescap Plc. | 2024-12-31 | 1.8 M | |
Goldman Sachs Group Inc | 2024-12-31 | 1.7 M | |
Sofinnova Ventures | 2024-12-31 | 1.6 M | |
Franklin Resources Inc | 2024-12-31 | 1.5 M | |
Fmr Inc | 2024-12-31 | 1.5 M | |
Lord, Abbett & Co Llc | 2024-12-31 | 1.4 M | |
Vanguard Group Inc | 2024-12-31 | 12.3 M | |
Blackrock Inc | 2024-12-31 | 9.2 M |
Natera Historical Income Statement
Natera Stock Against Markets
Natera Corporate Management
Michael MBA | Chief Officer | Profile | |
Olesya CPA | Chief Officer | Profile | |
LLM LLM | S Officer | Profile | |
Jonathan MEng | CoFounder Director | Profile | |
Sheetal Parmar | Head Services | Profile | |
Rishi Kacker | Chief Officer | Profile | |
Phil Grinnell | Vice Sales | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Natera Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Natera. If investors know Natera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Natera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share | Quarterly Revenue Growth 0.53 | Return On Assets | Return On Equity |
The market value of Natera Inc is measured differently than its book value, which is the value of Natera that is recorded on the company's balance sheet. Investors also form their own opinion of Natera's value that differs from its market value or its book value, called intrinsic value, which is Natera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Natera's market value can be influenced by many factors that don't directly affect Natera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Natera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Natera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Natera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.